The third patient, a 28-year-old woman with early-onset developmental delay, epilepsy, and movement disorders was treated with a ketogenic diet following the identification of a variant in <i>SLC2A1</i>, confirming a glucose transporter type 1 deficiency syndrome. The gene discussed is SLC2A1; the disease is epilepsy.